The Motley Fool

Avacta exploded higher, and I’m finding other strong-performing shares too

Image source: Getty Images.

On 3 April, the Avacta (LSE: AVCT) share price stood close to 20p. Today, it’s near 182p. You don’t need me to tell you how holding the stock could have transformed your portfolio.

The biotechnology company’s share price exploded higher when it announced an agreement with Cytiva to develop a saliva-based rapid antigen test to indicate whether a person has the Covid-19 infection.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Then, on 20 May, Avacta revealed it had entered a “global, exclusive, direct-to-consumer sales and marketing” agreement for its Covid-19 antigen test with Medusa 19 Ltd.

A substantial market for the Avacta test

Avacta’s chief executive, Dr Alastair Smith, said in the recent update the potential size of the market for the firm’s saliva test is “substantial.” He reckons the demand will come from businesses for workforce screening as well as directly from consumers.

It seems like a no-brainer to expect these tests to fly off the shelves in the current pandemic. But it remains unclear how profitable sales will be. And the company has invested significant sums of money into getting the test off the ground. Meanwhile, the coronavirus will only run for so long. The R (reproduction) value of the virus has been falling, and the market for tests could vanish if a vaccine arrives.

If I’d been lucky enough to have been holding shares in Avacta through the recent rises, I’d take at least some of my money off the table now and possibly all of it. I reckon investing can be at its best if we aim to run to where the ball is going rather than where it is now. For me, that means looking at other opportunities today.

And I’ve been finding some strong-performing shares in the stock market recently. Luckily, many haven’t exploded up so far and as fast as Avacta. But the trends are up, driven by resilient underlying business performance.

A stock-picker’s market

I reckon it pays to be selective though. It’s true that lockdowns are easing and many businesses can soon resume trading, such as retailers. But a world with coronavirus will be different, and that looks set to lead to reduced revenue and profits for many companies. Meanwhile, there are some sectors with uncertain futures, such as the hospitality industry and travel.

However, other sectors are doing well, such as IT, computing, healthcare, food supplies and others. In many cases, business hasn’t been affected much by the crisis and has sometimes been enhanced by it.

Right now, I like the look of shares such as Avast, Beeks Financial Cloud, Codemasters, Faron Pharmaceuticals, Genus and Sage, to name but a few. But don’t buy the shares without first researching and analysing the underlying business though.

If you like what you’re seeing after doing your own research, I reckon you’ll find other attractive opportunities in the sectors I’ve mentioned. And promising shares in other sectors too. Good hunting!

The high-calibre small-cap stock flying under the City’s radar

Adventurous investors like you won’t want to miss out on what could be a truly astonishing opportunity…

You see, over the past three years, this AIM-listed company has been quietly powering ahead… rewarding its shareholders with generous share price growth thanks to a carefully orchestrated ‘buy and build’ strategy.

And with a first-class management team at the helm, a proven, well-executed business model, plus market-leading positions in high-margin, niche products… our analysts believe there’s still plenty more potential growth in the pipeline.

Here’s your chance to discover exactly what has got our Motley Fool UK investment team all hot-under-the-collar about this tiny £350+ million enterprise… inside a specially prepared free investment report.

But here’s the really exciting part… right now, we believe many UK investors have quite simply never heard of this company before!

Click here to claim your copy of this special investment report — and we’ll tell you the name of this Top Small-Cap Stock… free of charge!

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.